Guilhem Richard is a member of Gide's Banking & Finance practice group. He specialises in capital markets, corporate finance and mergers and acquisitions.
He acts primarily as counsel to both issuers and lead arrangers on a wide range of market operations (in particular on IPOs, capital increases, private investments, block disposals and dual listings) as well as on the issuance of securities giving access to capital (OCEANE, ORA) and high-yield securities. His practice also covers external growth operations and issues related to corporate law, securities law and the governance of listed companies.
He has recently acted on the initial public offering of Erytech on Nasdaq and of Lysogene, Poxel, Electro Power System, and Pixium Vision on Euronext Paris. He was also instructed on the capital increases of Erytech, Poxel, DBV Technologies, Vallourec, Foncière des Murs, La Société de la Tour Eiffel, La Société des Bains de Mer, and on the issuance of bonds exchangeable or redeemable in shares for Air France, Ingenico and Assystem.
Prior to joining Gide in 2014, Guilhem worked for several years within the Corporate and Capital Markets teams of US and UK law firm offices in Paris. Guilhem holds a Master's degree from ESCP-Europe (2018), as well as postgraduate degrees in corporate law from Paris I University (2004) economic business law from Université Catholique de Louvain (Belgium, 2004), and business law from Paris II University (2003). He speaks French, English and Italian.
« Gide Loyrette Nouel A.A.R.P.I. has a core focus on French issuer IPOs, but also has in-depth knowledge of US instruments, including Nasdaq listings, Regulation S and 144A transactions. Arnaud Duhamel is the key adviser and cross-border specialist Melinda Stege Arsouze is particularly active in private placements in the US. Counsels Théophile Strebelle and Guilhem Richard provide significant support. Recent work includes acting for Lysogène and Société Générale on Lysogène’s IPO on compartment C of Euronext Paris; advising BNP Paribas on a €143m capital increase for Société de la Tour Eiffel through preferential subscription rights; and handling Gensight Biologics’ private placement to investors in the US and Europe. The team has a strong following in the biotech sector, where clients also include Erytech Pharma and Inventiva. Goldman Sachs, Jefferies and Veolia are also clients. »
Legal 500 EMEA 2018